Resources and links to further information about senolytics.
There is a growing body of evidence to support the efficacy of senolytic activators in humans. A number of clinical trials are currently underway to investigate the potential of these drugs to treat age-related diseases such as frailty, osteoarthritis, and type II diabetes. One study published in the journal Nature Medicine in 2018 found that a senolytic cocktail of the drugs dasatinib and quercetin was effective in reducing the number of senescent cells in elderly patients with osteoarthritis. This study showed that the treatment was associated with improved physical function and reduced pain. Another clinical trial, published in the journal JAMA Internal Medicine in 2019, found that the senolytic drug navitoclax was effective in reducing frailty and improving physical function in elderly patients. These studies provide strong evidence that senolytic activators have the potential to provide significant benefits to patients with age-related diseases. However, it is important to note that these studies are small and more research is needed to confirm the efficacy and safety of these drugs in humans. At this time, it is unclear if the sale of senolytic activators would fall under FDA regulations. The FDA has not yet issued any guidance on the sale of these drugs. Until more information is available, it is advisable to consult with a healthcare professional before purchasing or using senolytic activators. And for that reason always consult your doctor and only take supplements and vitamins under the direction of a doctor.